Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jounce Therapeutics Inc
(NQ:
JNCE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jounce Therapeutics Inc
< Previous
1
2
3
Next >
4 Analysts Have This to Say About Jounce Therapeutics
May 23, 2022
Jounce Therapeutics (NASDAQ:JNCE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
May 06, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading...
Via
Benzinga
Jounce Therapeutics: Q1 Earnings Insights
May 05, 2022
Jounce Therapeutics (NASDAQ:JNCE) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
55 Stocks Moving In Friday's Mid-Day Session
May 06, 2022
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Via
Benzinga
Jounce Therapeutics Q1 2022 Earnings Conference Call On May 5, 2022 At 08:00 AM ET
May 03, 2022
Jounce Therapeutics (NASDAQ:JNCE) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...
Via
Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
March 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...
Via
Benzinga
Recap: Jounce Therapeutics Q4 Earnings
March 02, 2022
Jounce Therapeutics (NASDAQ:JNCE) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Outlook For Jounce Therapeutics
March 01, 2022
Jounce Therapeutics (NASDAQ:JNCE) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement....
Via
Benzinga
Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript
November 06, 2021
JNCE earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 21, 2021
Gainers Viridian Therapeutics (NASDAQ:VRDN) shares rose 18.05% to $12.62 during Tuesday's pre-market session. The company's market cap stands at $120.9 million....
Via
Benzinga
Earnings Scheduled For March 2, 2022
March 02, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...
Via
Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
46 Biggest Movers From Yesterday
September 15, 2021
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
September 14, 2021
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares...
Via
Benzinga
Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript
August 05, 2021
JNCE earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Jounce Therapeutics Bounced Higher Today
June 15, 2021
The company gets a regulatory nod that will put $25 million in its pocket.
Via
The Motley Fool
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 15, 2021
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021
September 14, 2021
Upgrades Northcoast Research upgraded the previous rating for Casey's General Stores Inc ...
Via
Benzinga
Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
June 15, 2021
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25...
Via
Benzinga
Exposures
Product Safety
Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript
May 04, 2021
JNCE earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
3 Buy-Rated Biotech Stocks Under $10
April 20, 2021
The biotech industry has been at the center of investor attention over the past year thanks to the COVID-19 pandemic and an accompanying global race for a vaccine.
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.